2016 ACR/ARHP Annual Meeting Archives - Page 148 of 219

Abstract Number: 1555

E-Comorbidity: Evaluation of the Validity of Electronic Comorbidity Assessment in Identifying Comorbid Conditions Among Patients with Rheumatoid and Psoriatic Arthritis
Abstract Number: 2321

Early Damage and Mortality in a Cohort of Patients with Myositis Followed up to 20 Years
Abstract Number: 2472

Early DAS28 Drop Is a Predictor for Clinical Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis: An Observational Study of a Real Life Inception Cohort
Abstract Number: 489

Early Detection of Inflammatory Arthritis: The Role of Musculoskeletal Symptoms, Infections and Rheumatoid Arthritis-Related Comorbidities in Primary Care
Abstract Number: 1623

Early Effects of Tofacitinib on Bone Homeostasis in Patients with Rheumatoid Arthritis
Abstract Number: 1032

Early In Vivo Induction of Mouse Interferon-alpha1 Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis
Abstract Number: 115

Early Inflammatory Arthritis Presentation, Management and Outcomes in Canadian Aboriginal Patients
Abstract Number: 1457

Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease
Abstract Number: 1703

Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial
Abstract Number: 2045

Early Preeclampsia Risk in Lupus Pregnancy: A Swedish Population-Based Register Investigation
Abstract Number: 3104

Early Proteinuria Response in Real Life Situation Predicts Long-Term Lupus Renal Outcome in Ethnically Diverse Group with Biopsy-Proven Nephritis
Abstract Number: 3211

Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands
Abstract Number: 1619

EARTH EXPLORER 2, a Phase IIb Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and the Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis
Abstract Number: 325

Ebselen Is a Potential Anti-Osteoporosis Agent By Suppressing RANK Ligand-Induced Osteoclast Differentiation in Vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In Vivo
Abstract Number: 2630

EBV Load Quantification in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis Treated By Abatacept and Tocilizumab
Abstract Number: 2617

Economic Burden of Non-Responders to Biologic DMARD Treatments in Rheumatoid Arthritis
Abstract Number: 2229

Economic Burden of Rheumatoid Arthritis Is Higher for ACPA-Positive Patients
Abstract Number: 3168

Economic Evaluation of Damage Accrual in an International SLE Inception Cohort
Abstract Number: 2234

Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
Abstract Number: 609

Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)
Abstract Number: 2058

Ectonucleotidase-Mediated Protection of Lupus Mice from Exaggerated Immune Responses and Arterial Vasculopathy
Abstract Number: 421

Educating Patients on the Cardiovascular Risks of Rheumatoid Arthritis: Usual Care Versus a Structured Approach
Abstract Number: 323

Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Freedom Extension Study
Abstract Number: 2486

Effect of a Dynamic Exercise Program in Combination with a Mediterranean Diet in Strength, Joint Mobility and Disease Activity in Women with Rheumatoid Arthritis
Abstract Number: 2024

Effect of a Revised Counselor Training on Skills Development and Knowledge of Volunteers with Systemic Lupus Erythematosus
Abstract Number: 268

Effect of Abatacept Treatment on T Cells in Muscle Tissue and Peripheral Blood in Polymyositis and Dermatomyositis Patients
Abstract Number: 1273

Effect of Anti-Cyclic Citrullinated Protein Antibodies and Rheumatoid Factor on Bone Erosions in Early Rheumatoid Arthritis Patients Using HR-pQCT: A Cross-Sectional Study
Abstract Number: 2174

Effect of Anti-Rheumatic Treatment on Selenium Levels in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Abstract Number: 1640

Effect of BMI on Baricitinib Efficacy: Pooled Analysis from Two Phase 3 Rheumatoid Arthritis Clinical Trials
Abstract Number: 394

Effect of BMI on Symptoms and Outcomes in Juvenile Idiopathic Arthritis Patients
Abstract Number: 2379

Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes
Abstract Number: 372

Effect of Chronicity on Pain Behaviors in Collagenase Induced Non-Inflammatory Monoarthritis in Mice
Abstract Number: 2795

Effect of Complete or Partial Proteinuria Recovery Compared to No Recovery at 2 Years after the Diagnosis of Lupus Nephritis on Long Term Outcomes
Abstract Number: 1687

Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis
Abstract Number: 2L

Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
Abstract Number: 2633

Effect of Different Biologic Agents on Lipid Profile in Rheumatoid Arthritis
Abstract Number: 1764

Effect of Disease Remission on Organ Damage and Quality of Life in Chinese Patients with Systemic Lupus Erythematosus
Abstract Number: 1742

Effect of DMARD Therapies on NSAID Intake, Quality of Life, and Physical Functioning in Patients with Ankylosing Spondylitis
Abstract Number: 2371

Effect of Etanercept on Several Soluble Biomarkers in a Randomized Controlled Trial of Patients with Erosive Hand Osteoarthritis
Abstract Number: 2606

Effect of Glucocorticoids on Clinical and Radiographic Efficacy Outcomes in Methotrexate-Naive Patients with RA Receiving Tofacitinib or Methotrexate Monotherapy: Analysis of Data from a Phase 3 Trial
Abstract Number: 772

Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Abstract Number: 2549

Effect of Interleukin-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type 9 Serum Levels in Rheumatoid Arthritis Patients
Abstract Number: 1382

Effect of Lupus Anticoagulant on Rotational Thromboelastometry in Juvenile Systemic Lupus Erythematosus: Preliminary Data on a Single Center Cohort
Abstract Number: 2535

Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Abstract Number: 2372

Effect of Oxytocin on Osteoarthritis
Abstract Number: 1958

Effect of Poverty Status in 2009, % of Years in Poverty Between 2003 and 2009, and Exiting Poverty Permanently By 2009 on SLE Damage in 2015
Abstract Number: 2439

Effect of Pregnancy Counseling on the Outcome of Pregnancies in Women with Systemic Lupus Erythematosus: A Prospective Observational Study
Abstract Number: 2044

Effect of Pregnancy on Disease Flares in Patients with Systemic Lupus Erythematosus
Abstract Number: 1057

Effect of Quantitative Information Concerning Medication Side-Effects on Risk Perception
Abstract Number: 3070

Effect of Sarcopenia, Subcutaneous Adipose Tissue and Abdominal Visceral Fat on Mortality Risk of Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study
Abstract Number: 3091

Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate
Abstract Number: 2615

Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors
Abstract Number: 1434

Effect of Systemic and Local Inflammation on the Insulin Resistance and Glucose/Lipid Metabolism in Rheumatoid Arthritis: Humans and CIA Mouse Model
Abstract Number: 2054

Effect of Temporary Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Abstract Number: 2662

Effect of Tobacco Smoking on the Clinical, Histopathological, and Serological Manifestations of SjöGren’s Syndrome
Abstract Number: 621

Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis
Abstract Number: 981

Effectiveness of a Six-Week Hand Osteoarthritis Program in a Primary Care Setting
Abstract Number: 985

Effectiveness of a Web-Based Personalized Rheumatoid Arthritis Risk Tool with or without a Health Educator for Knowledge of RA Risk Factors
Abstract Number: 1337

Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
Abstract Number: 3206

Effectiveness of Childhood Vaccinations in CAPS Patients Treated with Canakinumab: Results from an Open-Label Phase III Extension Study
Abstract Number: 954

Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Abstract Number: 2324

Effects of 12 Weeks Low-Intensity Blood-Flow Restricted Resistance Training on Knee Extensor Strength in Patients with Sporadic Inclusion Body Myositis
Abstract Number: 378

Effects of a Natural Product Containing Specialized Pro-Resolving Mediators in Subjects with OA, RA, or Other Chronic Inflammatory Conditions in a Multi-Clinic Case Series
Abstract Number: 2084

Effects of a Web-Based Patient Decision Aid on Biologics for Rheumatoid Arthritis: A Proof-of-Concept Study
Abstract Number: 9

Effects of Alcohol Consumption on the Severity of Inflammation in Hand and Foot Joints Detected with MR Imaging
Abstract Number: 1158

Effects of an Educational Program Using Treat to Target Strategy in Korean Patients with Rheumatoid Arthritis
Abstract Number: 1748

Effects of Anti-High Mobility Group Box 1 Antibody for MRL/Lpr lupus-Prone Mice
Abstract Number: 2632

Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis
Abstract Number: 2444

Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis
Abstract Number: 97

Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study
Abstract Number: 727

Effects of Nsaids on Disease Activity in Ankylosing Spondylitis
Abstract Number: 349

Effects of Osteoporosis Treatments for Bone Loss and Pain-Related Behavior in the Hind Limb-Unloaded Mouse Model of Disuse Osteoporosis
Abstract Number: 39

Effects of Pregabalin (Lyrica®) on Cerebrospinal Fluid Substance P in Human Subjects with Fibromyalgia Syndrome
Abstract Number: 2236

Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Abstract Number: 760

Effects of Type I Interferon Inhibition on Blood Leukocyte Subsets in Patients Treated in a Phase IIb Clinical Study of Anifrolumab in SLE
Abstract Number: 622

Efficacy after Transition to SB5 from Reference Adalimumab (Humira®) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study
Abstract Number: 1690

Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results
Abstract Number: 12L

Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study
Abstract Number: 1586

Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials
Abstract Number: 692

Efficacy and Safety of Biological Therapy and Target Synthetic Dmards: A Systematic Literature Review Informing the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis
Abstract Number: 1329

Efficacy and Safety of Biologics in Relapsing Polychondritis: A National Multicenter Study in France
Abstract Number: 2380

Efficacy and Safety of Canakinumab in Patients Aged One to Six Years with Cryopyrin-Associated Periodic Syndromes: Results of an Open-Label, Phase III Extension Study
Abstract Number: 9L

Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: 40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial
Abstract Number: 3205

Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD AND TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
Abstract Number: 2374

Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Follow-up Study
Abstract Number: 2555

Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis
Abstract Number: 1635

Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Abstract Number: 295

Efficacy and Safety of Fasinumab for Osteoarthritic Pain in Patients with Moderate to Severe Osteoarthritis of the Knees or Hips
Abstract Number: 943

Efficacy and Safety of IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever Who Underwent Kidney Transplantation
Abstract Number: 625

Efficacy and Safety of Intravenous Golimumab Plus Methotrexate in Patients 65 Years and Younger and Those Greater Than 65 Years of Age-a Post-Hoc Analysis
Abstract Number: 959

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
Abstract Number: 3222

Efficacy and Safety of Monotherapy with Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study
Abstract Number: 733

Efficacy and Safety of Non-Biological Therapy (Non-Biological Drugs and Non-Pharmacological Interventions): A Systematic Literature Review for the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis
Abstract Number: 1632

Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies
Abstract Number: 3221

Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-Blind, Monotherapy Study in Patients with Active Rheumatoid Arthritis with Intolerance or Inadequate Response to Methotrexate
Abstract Number: 3223

Efficacy and Safety of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study
Abstract Number: 602

Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study
Abstract Number: 1591

Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis
Abstract Number: 911

Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: 976

Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis: Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial in Japan
Abstract Number: 10L

Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Abstract Number: 2983

Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo‑Controlled, Phase 3 Trial
Abstract Number: 1364

Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients
Abstract Number: 4L

Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 3056

Efficacy of a Work Disability Prevention Program for People with Rheumatic and Musculoskeletal Conditions: A Randomized Controlled Trial
Abstract Number: 2968

Efficacy of Anti-TNF Alpha in Severe and Refractory Cardiovascular Involvement of Behcet’s Disease: A Multicenter Observational Study of 18 Patients
Abstract Number: 1343

Efficacy of Biological-Targeted Treatments in MDS-Related Systemic Autoimmune Diseases: Multicenter Retrospective Study of 28 Patients
Abstract Number: 53

Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study
Abstract Number: 246

Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis
Abstract Number: 245

Efficacy of Cyclophosphamide Therapy in Idiopathic Retroperitoneal Fibrosis in a Retrospective Monocentric Analysis
Abstract Number: 712

Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis (nr-axSpA): Subgroup Analysis By Baseline MRI and C-Reactive Protein Status
Abstract Number: 861

Efficacy of Methotrexate in Giant Cell Arteritis
Abstract Number: 49

Efficacy of Mirogabalin on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase 2 Proof-of-Concept Study
Abstract Number: 3248

Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Abstract Number: 848

Efficacy of Prucalopride in the Treatment of Systemic Sclerosis-Related Intestinal Involvement: Results from an Open Label Cross-over Study
Abstract Number: 1896

Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases
Abstract Number: 2894

Efficacy of Rituximab in Systemic Sclerosis with Interstitial Lung Disease
Abstract Number: 3224

Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Based upon Prior Use of Non-Anti-TNF Biologics in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global Phase 3 Study
Abstract Number: 1736

Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study
Abstract Number: 1609

Efficacy of Tofacitinib in Patients Who Are Inadequate Responders to Disease-Modifying Antirheumatic Drugs According to Early Versus Late Duration of Rheumatoid Arthritis: Post-Hoc Analysis of Data from Phase 3 Trials
Abstract Number: 1117

EGCG Down-Regulates TNF-α-Induced Mcl-1 Expression By Modulating Mule/Huwe1, β-TrCP, and USP9X Ubiquitin/De-Ubiquitin Ligases in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 2672

Elderly Patients Risk a False Positive Diagnosis of Primary Sjogren’s Syndrome If a Positive Labial Gland Biopsy Is Solely Based on Focus Score
Abstract Number: 1483

Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer Is Associated with Increased Cardiovascular Risk
Abstract Number: 2725

Elevated Disease Activity in Disease-Related Spondyloarthritis Despite Use of Tumor Necrosis Factor Inhibitor Therapies
Abstract Number: 1904

Elevated GITRL Is Associated with Multi-Organ Involvement and Increased Disease Activity of Primarty Sjogren’s Syndrome and Promotes Pathogenic Th1/17 Differentiation
Abstract Number: 2706

Elevated Levels of Serum Myeloid Related Protein 8/14 in Ankylosing Spondylitis: Associated with Peripheral Arthritis and Active Disease
Abstract Number: 2577

Elevated Matrix Metalloproteinases Levels in Oral Fluids of Most Rheumatoid Arthritis Patients, Even without Frank Periodontitis
Abstract Number: 3017

Elevated Neutrophil Extracellular Trap Levels Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA Levels in the Sputum of Individuals at-Risk for Future Rheumatoid Arthritis
Abstract Number: 1839

Elevated Plasma Cell-Free Mitochondrial DNA Defines a Subgroup of Lupus Patients with Membranous Lupus Nephritis
Abstract Number: 1078

Elevated Proportion of CD38highIgD+ b Cells in Peripheral Blood Is Related to Disease Activity in Patients with Primary SjöGren’s Syndrome
Abstract Number: 1010

Elucidating the Activation Profile of Systemic Sclerosis Macrophages
Abstract Number: 2931

Endogenous Nur77 Is a Specific Indicator of Antigen Receptor Signaling in Human T and B Cells
Abstract Number: 176

Endoplasmic Reticulum Stress Induces Lupus Kidney Disease By Facilitating Antigen Cross-Presentation Via the Increase of Endosomal Sec61
Abstract Number: 3044

Endothelin 1 Induces a Myofibroblastic Phenotype in Vascular Smooth Muscle Cells. A Mechanism Potentially Contributing to Vascular Remodeling and Intimal Hyperplasia in Giant Cell Arteritis
Abstract Number: 1459

Enhanced Efficacy of Early Vs. Late IL-1β Antagonism in Murine Arthritis Mediated By Deficiency of the IL-1 Receptor Antagonist IL-1ra
Abstract Number: 1563

Enhanced Expression of mRNA for Response Gene to Complement 32 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Abstract Number: 1137

Enhancing Pediatric Rheumatology Education through Computer-Assisted Fellow-Taught Case Modules
Abstract Number: 1305

Enriching Rheumatoid Arthritis Trial Cohorts with Erosion Progressors By Screening for Active Erosions (Erosions with Osteitis) with MRI
Abstract Number: 64

Enrichment of Immune Pathways in Genes Under Geographically Restricted Adaptation in the Gullah African American Population of South Carolina
Abstract Number: 2011

Enteric-Coated Mycophenolate Sodium Versus Azathioprine for Patients with Moderate/Severe Active Systemic Lupus Erythematosus: Results from a Phase 3, Randomized, Parallel, Multicentre Study
Abstract Number: 399

Enthesitis in Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 3038

Enumeration and Preliminary Characterisation of Peri-Entheseal Bone Type 3 Innate Lymphoid Cells
Abstract Number: 1221

Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative
Abstract Number: 243

Eosinophilic Angiocentric Fibrosis : A Mimic of Vasculitis in IgG4 Related Disease Spectrum
Abstract Number: 2459

Epidemiologic Profile of Erectile Dysfunction in SLE: A Multi-Center Study in Latin American Patients
Abstract Number: 1814

Epidemiology and Microbiology of Pneumonia in Systemic Lupus Erythematosus (SLE)
Abstract Number: 3190

Epidemiology of Polymyalgia Rheumatica 2000-2014: A Population Based Study
Abstract Number: 68

Epigenetic and Expression Analysis of Ankylosing Spondylitis Association Loci Point to Key Cell Types Driving Disease
Abstract Number: 661

Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction
Abstract Number: 2665

Epratuzumab Treatment of Patients with Systemic Lupus Erythematosus and Secondary Sjogren’s Syndrome: An Exploratory Analysis of Phase 3 Studies
Abstract Number: 471

Epstein-Barr Virus-Induced Expression of Receptor Activator Nuclear Factor-κb Ligand on B Cells Is Possibly Responsible for Erosive Arthritis in Epstein-Barr Virus-Infected Humanized Nonobese Diabetic/Shi-Scid/γcnull Mice
Abstract Number: 656

ERdj5 Function Is Involved in Inflammatory Manifestations of Sjögren’s Syndrome in the Salivary Glands
Abstract Number: 2458

Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review
Abstract Number: 933

Erosion Patterns in Seropositive and Seronegative Rheumatoid Arthritis: A Joint-By-Joint Approach
Abstract Number: 1884

Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis
Abstract Number: 2016

Esophageal Disease in Systemic Sclerosis: Does Heritability Play a Role?
Abstract Number: 838

Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Abstract Number: 2675

Essdai, Clinessdai and DAS Scoring at Diagnosis of Primary Sjogren Syndrome: Association with the Development of Hematologic and Solid Neoplasias in 1301 Patients
Abstract Number: 1244

Establishing a Case Report Form (CRF) for Systemic Autoimmune Diseases Studies
Abstract Number: 1413

Establishing Clinical Severity for Patient Reported Outcomes Measurement Information System Measures in Adult Patients with Rheumatic Diseases
Abstract Number: 2392

Establishing Quality of Life Content Domains in Pediatric Localized Scleroderma
Abstract Number: 915

Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface
Abstract Number: 796

Establishment of an International Autoantibody Standard for Anti-DFS70/LEDGF Antibodies: Proof-of-Concept Study for a Novel Strategy for the Setting up of International Autoantibody Standards
Abstract Number: 2252

Estimated Cost of SLE Hospitalizations
Abstract Number: 1431

Estimates of Global Status By Physicians and Patients Are More Likely to be Discordant in Osteoarthritis Than in Rheumatoid Arthritis
Abstract Number: 1039

Estimation of the Risk of Developing Rheumatoid Arthritis in High-Risk Subjects : Systematic Review and Meta-Analysis
Abstract Number: 2579

Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis
Abstract Number: 264

Ethnicity-Related Differences in the Clinical Presentation of Sarcoidosis in Spain (SARCOGEAS-SEMI Registry)
Abstract Number: 2678

EULAR Primary SjöGren’s Syndrome Disease Activity Index (ESSDAI), Results from the National Registry of the Spanish Society of Rheumatology (SJÖGRENSER)
Abstract Number: 776

Eurolupus and Low Steroid Regimen in Proliferative Lupus Nephritis: Retrospective Evaluation of 38 Patients in the Black Population of Martinique
Abstract Number: 411

Evaluating Levels of Activity and Health-Related Quality of Life in a Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Abstract Number: 2727

Evaluating Psoriatic Arthritis and Psoriasis Skin Lesions: Ultrasound As a Complementary Measure
Abstract Number: 1288

Evaluating Rheumatoid Arthritis Disease Activity Using Global Assessment of 18f-FDG Uptake in the Joints
Abstract Number: 1053

Evaluating the Charla De Lupus (Lupus Chat)® Program’s Teen, Young Adult and Parent Support Group: Reaching the Hispanic/Latino Community through a Family Model of Support
Abstract Number: 2048

Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study
Abstract Number: 1037

Evaluation of 14-3-3η As a Tool for Diagnosis of Early RA in a European Cohort
Abstract Number: 341

Evaluation of 25-Hydroxyvitamin D Levels in Rheumatologic Diseases
Abstract Number: 3113

Evaluation of a Clinical Transition Pathway for Adolescents with Autoimmune Diseases
Abstract Number: 1253

Evaluation of a Pre-Assessment Tool to Define the Spectrum of Autoimmune Diseases in an Underserved Environment
Abstract Number: 1948

Evaluation of Body Composition Parameters in Granulomatosis with Polyangiitis: Association of Fat Mass Parameters with Disease Activity and Inflammatory Markers
Abstract Number: 2323

Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis
Abstract Number: 1600

Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib By RAPID3: An Analysis of Data from 6 Phase 3 Studies
Abstract Number: 2382

Evaluation of Intestinal Inflammation in Children with FMF
Abstract Number: 1387

Evaluation of Mild to Moderate SLE Flare in Patients with Childhood-Onset Disease
Abstract Number: 362

Evaluation of Osteoporosis Risk Factors in Lung Transplant Patients
Abstract Number: 2451

Evaluation of Ovarian Reserve and Function in Adolescent Females with Systemic Lupus Erythematosus
Abstract Number: 85

Evaluation of Patient Satisfaction with the on-Tracc Program; Benefits of a Joint Approach
Abstract Number: 1379

Evaluation of S100 Proteins As Potential Biomarkers of Global and Renal-Specific Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1275

Evaluation of Spine and Tibia Bone Microarchitecture Using Trabecular Bone Score (TBS) and HR-pQCT in Patients with Ankylosing Spondylitis
Abstract Number: 1226

Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets
Abstract Number: 749

Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis
Abstract Number: 478

Evaluation of the Relationship Between Methotrexate Polyglutamation and Efficacy in the Collagen-Induced Arthritis Mouse Model
Abstract Number: 1373

Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
Abstract Number: 2664

Evaluation of Thyroid Autoimmune Disease in Primary SjöGren’s Syndrome and Its Association with Disease Phenotype
Abstract Number: 155

Evaluation of Ultrasonography As Modality for Identification of Calcium Crystal Deposits in Patients of Primary Osteoarthritis of Knee Joint
Abstract Number: 775

Evaluation of Use of Belimumab in Clinical Practice Settings: Results in Argentina
Abstract Number: 1366

Evidence Based Criteria for Corticosteroid Tapering/Discontinuation. an Analysis of the Paediatric Rheumatology International Trials Organization (PRINTO) Trial in New Onset Juvenile Dermatomyositis
Abstract Number: 2184

Evidence Based Physical Activity Threshold to Predict Improved/High Function in Older Adults with Lower Extremity Conditions: The Osteoarthritis Initiative
Abstract Number: 1921

Evidence for Prevotella Copri As an Immune-Relevant Bacterium in Rheumatoid Arthritis
Abstract Number: 373

Evidence for TMJ Pain As a Component of a Generalized Pain Phenotype
Abstract Number: 3030

Evidence of Inflammasome Activation in the Peripheral Blood and Salivary Gland Tissues of Primary Sjögren’s Syndrome Patients: Correlation with Clinical Indices of Severe Disease and Lymphoma Development
Abstract Number: 1516

Evidence of Labial Salivary Gland Epithelial Cell Activation from Patients with Rheumatoid Arthritis and Sicca Symptomatology
Abstract Number: 2274

Evidence of Phospho-Degron Regulating Expression of Urate Secretory Transporter ABCG2
Abstract Number: 2693

Evolution of Disease Activity over a 5-Year Period in the 395 Patients with Primary SjöGren’s Syndrome of the Assess Prospective Cohort
Abstract Number: 2722

Evolution over Thirty Years of the Profile of Inpatients with Reactive Arthritis in a Tertiary Rheumatology Unit
Abstract Number: 535

Examination of Diurnal and Daily Variation of the Multi-Biomarker Disease Activity (MBDA) Score in RA to Establish the Minimally Important Difference
Abstract Number: 208

Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout
Abstract Number: 1891

Excellent Reliability of Semiquantitative Nailfold Capillaroscopy Assessment in a Systemic Sclerosis Cohort – a Pilot Study
Abstract Number: 826

Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients
Abstract Number: 1883

Exercise Habits and Factors Associated with Exercise in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study
Abstract Number: 2860

Exercise Significantly Improves Cardiorespiratory Fitness and Reduces Disease-Related Fatigue without Adverse Effects on Disease Activity in Systemic Lupus Erythematosus: a Systematic Review with Meta-Analysis
Abstract Number: 2277

Exon Sequencing Reveals a Significant Burden of Non-Synonymous Variants in Both SLC22A11 (OAT4) and SLC22A12 (URAT1) in European Hyperuricemic Individuals
Abstract Number: 1092

Expansion of Age Associated B Cells in Murine Lupus Is Regulated By DEF6 and Its Homologue Swap-70
Abstract Number: 1088

Expansion of Transitional B Cells in SLE Patients Correlates with Increased Toll-like Receptor 7 Expression
Abstract Number: 329

Explore the Possible Mechanisms of 1,25(OH)2D3 on the Formation of Osteoclasts in Rheumatoid Arthritis
Abstract Number: 1153

Exploring Perceptions of a Rheumatoid Arthritis Specific Smoking Cessation Programme
Abstract Number: 488

Exploring the Association Between Air Pollutant Exposure and Seropositivity in Rheumatoid Arthritis
Abstract Number: 1477

Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project
Abstract Number: 1484

Exploring the Link Between RA Disease Activity, Lipid Levels, and Cardiovascular Disease in an Early Inflammatory Arthritis Cohort
Abstract Number: 2005

Exploring the Window of Opportunity for Drug-Free Clinical Remission in Patients with Active, Very Early Peripheral Spondyloarthritis
Abstract Number: 2114

Exposure to Carbamylated Self- and Non-Self-Proteins Can Lead to a Break-of -Tolerance and the Induction of Autoimmunity
Abstract Number: 643

Exposure-Response Analyses of Efficacy of ABT-122, a Dual-Variable Domain Immunoglobulin (DVD-Ig™) Targeting TNF-α and IL-17A, Compared with Adalimumab in Subjects with Rheumatoid Arthritis and Background MTX
Abstract Number: 761

Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients with Systemic Lupus Erythematosus
Abstract Number: 874

Expression and Function of IL-12/23 Related Cytokine Subunits (p35, p40 and p19) in Giant-Cell Arteritis Lesions. Potential Role of p40 in Promoting Th1 -Mediated Pathways
Abstract Number: 2885

Expression Levels and Function of the Inhibitory Molecule, Immunoglobulin like Transcript 7 (ILT7), Are Decreased on Circulating Plasmacytoid Dendritic Cells in SLE Patients with High ANA Titers
Abstract Number: 278

Expression of Anti-Microbial Peptide LL-37 Correlates to the Activation of Type I Interferon Pathway in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1744

Expression of C1q By Podocytes at Late Stages of Proliferative Lupus Glomerulonephritis
Abstract Number: 3239

Expression of IFN-Regulated Genes in Autoantibody Exposed Babies in Utero
Abstract Number: 2071

Expression of Neuraminidase 1 (NEU1) Is Upregulated in the Lungs of Scleroderma Patients with Pulmonary Fibrosis, and Gene Delivery of NEU1 to Mouse Lungs Elicits Accumulation of CD8+ Lymphocytes and Collagen
Abstract Number: 660

Expression of the Chemokine Receptor CXCR5 Is Decreased in the Periphery of Patients with Primary Sjogren’s Syndrome
Abstract Number: 657

Expression of Type-III Interferons (IFNλs) and Their Receptor in Sjögren’s Syndrome
Abstract Number: 1473

Expression of Vitamin D Receptor Associated Genes in the Aorta of Coronary Artery Disease Patients with and without Rheumatoid Arthritis
Abstract Number: 2962

Expression Profile of Chemokines Is Skewed to Th17/Th22 Recruitment in Circulation of Patients with Behcet’s Disease
Abstract Number: 1303

Extended T2-Times in Cardiovascular Magnetic Resonance (CMR) in Patients with Systemic Lupus Erythematosus (SLE) and Persisted Dyspnoea: Is SLE-Associated Myocarditis an Underestimated Problem?
Abstract Number: 1218

Extensive Genetic Overlap of Traits Related to Gout, Hyperuricemia and Its Comorbidities
Abstract Number: 2129

Extracellular Adenosine Deficiency Plays a Role in the Pathogenesis of Osteoarthritis (OA) and Adenosine Replacement Prevents Post-Traumatic Osteoarthritis
Abstract Number: 283

Extracellular Histidyl-tRNA Synthetase in Myositis
Abstract Number: 1127

Extracellular Macrophage Migration Inhibitory Factor Is Essential for Hypoxia-Induced Angiogenesis in a Hypoxia Inducible Factor Independent Manner
Abstract Number: 1114

Extracellular Vesicles in the Circulating of Rheumatoid Arthritis Patients Are Pro-Inflammatory
Abstract Number: 820

EZH2 Modulates Angiogenesis and Fibrosis in Scleroderma